ACLARIS THERAPEUTICS INC

Watch Aclaris Therapeutics’ Q2 2026 earnings: 52‑week high of $6.51 driven by Bosakitug Phase 2 progress and early contract revenue, boosting investor confidence.

Aclaris Therapeutics’ short interest has decreased by 34.8% in April, potentially indicating growing investor confidence despite the company’s volatile stock price.